{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:49:35Z","timestamp":1757778575393},"reference-count":39,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2017.3205","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T12:20:58Z","timestamp":1508502058000},"source":"Crossref","is-referenced-by-count":9,"title":["Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib"],"prefix":"10.3892","author":[{"given":"Yanhong","family":"Cheng","sequence":"first","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchan","family":"Hao","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaojie","family":"Hu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Wu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiucai","family":"Xu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"key20200713174401_b1-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"key20200713174401_b2-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"key20200713174401_b3-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.leukres.2015.11.008","article-title":"Dasatinib first-line: Multicentric Italian experience outside clinical trials","volume":"40","author":"Breccia","year":"2016","journal-title":"Leuk Res"},{"key":"key20200713174401_b4-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"key20200713174401_b5-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"e0114828","DOI":"10.1371\/journal.pone.0114828","article-title":"Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor","volume":"10","author":"Vaidya","year":"2015","journal-title":"PLoS One"},{"key":"key20200713174401_b6-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","article-title":"The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib","volume":"127","author":"Parker","year":"2016","journal-title":"Blood"},{"key":"key20200713174401_b7-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"key20200713174401_b8-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1182\/blood-2011-01-332569","article-title":"STAT5 as a CML target: STATinib therapies?","volume":"117","author":"Turhan","year":"2011","journal-title":"Blood"},{"key":"key20200713174401_b9-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4161\/cc.25116","article-title":"Adding a new facet to STAT5 in CML: Multitasking for leukemic cells","volume":"12","author":"Warsch","year":"2013","journal-title":"Cell Cycle"},{"key":"key20200713174401_b10-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"key20200713174401_b11-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"key20200713174401_b12-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"30487","DOI":"10.18632\/oncotarget.5890","article-title":"Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells","volume":"6","author":"Carter","year":"2015","journal-title":"Oncotarget"},{"key":"key20200713174401_b13-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"key20200713174401_b14-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"key20200713174401_b15-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00277-010-1125-8","article-title":"The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)","volume":"90","author":"Dong","year":"2011","journal-title":"Ann Hematol"},{"key":"key20200713174401_b16-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-016-0359-x","article-title":"Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr\/Abl-dependent and Bcr\/Abl-independent mechanisms","volume":"9","author":"Lan","year":"2016","journal-title":"J Hematol Oncol"},{"key":"key20200713174401_b17-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation","volume":"20","author":"Shi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20200713174401_b18-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"e0123314","DOI":"10.1371\/journal.pone.0123314","article-title":"A Novobiocin derivative, XN4, inhibits the proliferation of chronic myeloid leukemia cells by inducing oxidative DNA damage","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"key20200713174401_b19-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1093\/nar\/gkl1169","article-title":"An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans","volume":"35","author":"Ismail","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"key20200713174401_b20-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.phymed.2016.05.008","article-title":"Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells","volume":"23","author":"Ren","year":"2016","journal-title":"Phytomedicine"},{"key":"key20200713174401_b21-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1089\/ars.2011.4434","article-title":"Redox regulation of p53, redox effectors regulated by p53: a subtle balance","volume":"16","author":"Maillet","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"key20200713174401_b22-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejps.2013.11.009","article-title":"ROS and RNS induced apoptosis through p53 and iNOS mediated pathway by a dibasic hydroxamic acid molecule in leukemia cells","volume":"52","author":"Banerjee","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"key20200713174401_b23-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"key20200713174401_b24-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"key20200713174401_b25-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/0019-509X.98918","article-title":"Optimizing second-line therapy for chronic myeloid leukemia","volume":"49","author":"Raja","year":"2012","journal-title":"Indian J Cancer"},{"key":"key20200713174401_b26-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"key20200713174401_b27-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"key20200713174401_b28-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation","volume":"107","author":"Hoelbl","year":"2006","journal-title":"Blood"},{"key":"key20200713174401_b29-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20200713174401_b30-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1749-6632.2010.05192.x","article-title":"Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence","volume":"1197","author":"Mallette","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"key20200713174401_b31-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713174401_b32-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ceb.2014.09.010","article-title":"ROS-dependent signal transduction","volume":"33","author":"Reczek","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"key20200713174401_b33-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1038\/onc.2010.140","article-title":"DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation","volume":"29","author":"Brem","year":"2010","journal-title":"Oncogene"},{"key":"key20200713174401_b34-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7150\/ijbs.4283","article-title":"Surf the post-translational modification network of p53 regulation","volume":"8","author":"Gu","year":"2012","journal-title":"Int J Biol Sci"},{"key":"key20200713174401_b35-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200713174401_b36-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"key":"key20200713174401_b37-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: Mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"key20200713174401_b38-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3892\/mmr.2015.4672","article-title":"p53 causes butein mediated apoptosis of chronic myeloid leukemia cells","volume":"13","author":"Woo","year":"2016","journal-title":"Mol Med Rep"},{"key":"key20200713174401_b39-ijmm-41-01-0455","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T18:10:15Z","timestamp":1594663815000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2017.3205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3892\/ijmm.2017.3205","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}